Jukier Tom, Gross Amanda, Boothe Dawn
Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
Scott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.
Front Vet Sci. 2024 Jan 5;10:1307888. doi: 10.3389/fvets.2023.1307888. eCollection 2023.
Phenobarbital has been used for many decades in both human and veterinary epileptic patients. Many formulations for a particular drug exist, most of which are marketed for humans. Recently a veterinary specific phenobarbital product has been introduced to the market in the United States. Utilizing a specific formulation to treat patients may help decrease the issue of bioequivalence between one pharmaceutical product to another. Therefore, the goal of this study was to determine single and multiple dosing pharmacokinetics and tolerability of a veterinary specific phenobarbital product over a 4-week time period.
8 Healthy dogs from a canine research colony were used in the study.
Overall, this phenobarbital formulation was well tolerated in the dogs in this study. Cmax, Tmax, half-life, and AUC after single 12 mg/kg oral dose were 23.5 μg/mL, 4.2 h, 94 h, and 2,758 hμg/mL. Following chronic dosing, these parameters were 29.1 μg/mL, 3.4 h, 70 h, and 2,971 hμg/mL, respectively.
This formulation demonstrated a mean absolute bioavailability of 100%, with similar pharmacokinetic properties to previously published data.
苯巴比妥已在人类和兽医癫痫患者中使用了数十年。一种特定药物存在多种制剂，其中大多数面向人类市场销售。最近，一种美国市场推出的兽用苯巴比妥产品。使用特定制剂治疗患者可能有助于减少一种药品与另一种药品之间生物等效性的问题。因此，本研究的目的是确定一种兽用苯巴比妥产品在4周时间内的单剂量和多剂量药代动力学及耐受性。
本研究使用了来自犬类研究群体的8只健康犬。
总体而言，本研究中的犬对这种苯巴比妥制剂耐受性良好。单次口服12 mg/kg剂量后的Cmax、Tmax、半衰期和AUC分别为23.5 μg/mL、4.2小时、94小时和2,758小时μg/mL。长期给药后，这些参数分别为29.1 μg/mL、3.4小时、70小时和2,971小时μg/mL。
该制剂的平均绝对生物利用度为100%，药代动力学特性与先前发表的数据相似。
